10802-1-AP

antibody from Proteintech Group

Targeting: GMNN Gem

Provider product page for 10802-1-AP

Western blot

ELISA

Immunocytochemistry

Immunoprecipitation

Immunohistochemistry

Flow cytometry

Antibody data

Antibody Data
Antigen structure
References [54]
Comments [0]
Validations
Western blot [1]
Immunoprecipitation [1]
Immunohistochemistry [1]

Submit

Product number: 10802-1-AP - Provider product page
Provider: Proteintech Group
Proper citation: Proteintech Cat#10802-1-AP, RRID:AB_2110945
Product name: Geminin antibody
Antibody type: Polyclonal
Description: Geminin antibody (Cat. #10802-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: FC, IF, IHC, IP, WB,ELISA.
Reactivity: Human, Mouse, Rat
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

GMNN protein structure - 10802-1-AP shown in red.

Submitted references A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.

Hutten SJ, de Bruijn R, Lutz C, Badoux M, Eijkman T, Chao X, Ciwinska M, Sheinman M, Messal H, Herencia-Ropero A, Kristel P, Mulder L, van der Waal R, Sanders J, Almekinders MM, Llop-Guevara A, Davies HR, van Haren MJ, Martin NI, Behbod F, Nik-Zainal S, Serra V, van Rheenen J, Lips EH, Wessels LFA, Grand Challenge PRECISION Consortium, Wesseling J, Scheele CLGJ, Jonkers J
Cancer cell 2023 May 8;41(5):986-1002.e9

DNA replication initiation factor RECQ4 possesses a role in antagonizing DNA replication initiation.

Xu X, Chang CW, Li M, Omabe K, Le N, Chen YH, Liang F, Liu Y
Nature communications 2023 Mar 4;14(1):1233

RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma.

Kim K, Kim SH, Lee JY, Kim YN, Lee ST, Park E
Journal of gynecologic oncology 2023 Jul;34(4):e45

CDT1 inhibits CMG helicase in early S phase to separate origin licensing from DNA synthesis.

Ratnayeke N, Baris Y, Chung M, Yeeles JTP, Meyer T
Molecular cell 2023 Jan 5;83(1):26-42.e13

A CRISPR-Cas9 screen identifies EXO1 as a formaldehyde resistance gene.

Gao Y, Guitton-Sert L, Dessapt J, Coulombe Y, Rodrigue A, Milano L, Blondeau A, Larsen NB, Duxin JP, Hussein S, Fradet-Turcotte A, Masson JY
Nature communications 2023 Jan 24;14(1):381

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.

Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, Vila-Casadesús M, Turpin A, Neuzillet C, Frigola J, Querol J, Yáñez-Bartolomé M, Castet F, Fabregat-Franco C, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernadó-Morales C, Haro N, Giles FJ, Pozo ÓJ, Miquel JM, Nuciforo PG, Vivancos A, Melé M, Serra V, Arribas J, Tabernero J, Peiró S, Macarulla T, Tian TV
Clinical cancer research : an official journal of the American Association for Cancer Research 2023 Jan 17;29(2):432-445

Ex Vivo Functional Assay for Evaluating Treatment Response in Tumor Tissue of Head and Neck Squamous Cell Carcinoma.

Capala ME, Pachler KS, Lauwers I, de Korte MA, Verkaik NS, Mast H, Jonker BP, Sewnaik A, Hardillo JA, Keereweer S, Monserez D, Koljenovic S, Mostert B, Verduijn GM, Petit S, van Gent DC
Cancers 2023 Jan 12;15(2)

Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.

Sundararajan V, Tan TZ, Lim D, Peng Y, Wengner AM, Ngoi NYL, Jeyasekharan AD, Tan DSP
The Journal of pathology 2023 Feb;259(2):194-204

Performance of a RAD51-based functional HRD test on paraffin-embedded breast cancer tissue.

van Wijk LM, Vermeulen S, Ter Haar NT, Kramer CJH, Terlouw D, Vrieling H, Cohen D, Vreeswijk MPG
Breast cancer research and treatment 2023 Dec;202(3):607-616

Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.

Ter Brugge P, Moser SC, Bièche I, Kristel P, Ibadioune S, Eeckhoutte A, de Bruijn R, van der Burg E, Lutz C, Annunziato S, de Ruiter J, Masliah Planchon J, Vacher S, Courtois L, El-Botty R, Dahmani A, Montaudon E, Morisset L, Sourd L, Huguet L, Derrien H, Nemati F, Chateau-Joubert S, Larcher T, Salomon A, Decaudin D, Reyal F, Coussy F, Popova T, Wesseling J, Stern MH, Jonkers J, Marangoni E
Nature communications 2023 Apr 7;14(1):1958

Lysophosphatidic acid suppresses apoptosis of high-grade serous ovarian cancer cells by inducing autophagy activity and promotes cell-cycle progression via EGFR-PI3K/Aurora-A(Thr288)-geminin dual signaling pathways.

Zhao H, Jia P, Nanding K, Wu M, Bai X, Morigen M, Fan L
Frontiers in pharmacology 2022;13:1046269

A Lack of Effectiveness in the ATM-Orchestrated DNA Damage Response Contributes to the DNA Repair Defect of HPV-Positive Head and Neck Cancer Cells.

Köcher S, Zech HB, Krug L, Gatzemeier F, Christiansen S, Meyer F, Rietow R, Struve N, Mansour WY, Kriegs M, Petersen C, Betz C, Rothkamm K, Rieckmann T
Frontiers in oncology 2022;12:765968

Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer.

Tao M, Sun F, Wang J, Wang Y, Zhu H, Chen M, Liu L, Liu L, Lin H, Wu X
Pharmacological research 2022 May;179:106232

Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer.

Stanzione M, Zhong J, Wong E, LaSalle TJ, Wise JF, Simoneau A, Myers DT, Phat S, Sade-Feldman M, Lawrence MS, Hadden MK, Zou L, Farago AF, Dyson NJ, Drapkin BJ
Science advances 2022 May 13;8(19):eabn1229

IKKε Inhibitor Amlexanox Promotes Olaparib Sensitivity through the C/EBP-β-Mediated Transcription of Rad51 in Castrate-Resistant Prostate Cancer.

Gilbert S, Péant B, Mes-Masson AM, Saad F
Cancers 2022 Jul 28;14(15)

Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.

Guffanti F, Alvisi MF, Anastasia A, Ricci F, Chiappa M, Llop-Guevara A, Serra V, Fruscio R, Degasperi A, Nik-Zainal S, Bani MR, Lupia M, Giavazzi R, Rulli E, Damia G
British journal of cancer 2022 Jan;126(1):120-128

Increased replication stress and R-loop accumulation in EGFRvIII-expressing glioblastoma present new therapeutic opportunities.

Struve N, Hoffer K, Weik AS, Riepen B, Krug L, Cetin MH, Burmester J, Ott L, Liebing J, Gatzemeier F, Müller-Goebel J, Gerbach M, Bußmann L, Parplys AC, Unger K, Mansour WY, Schüller U, Rieckmann T, Petersen C, Rothkamm K, Short SC, Kriegs M
Neuro-oncology advances 2022 Jan-Dec;4(1):vdab180

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture.

Chakrabarty S, Quiros-Solano WF, Kuijten MMP, Haspels B, Mallya S, Lo CSY, Othman A, Silvestri C, van de Stolpe A, Gaio N, Odijk H, van de Ven M, de Ridder CMA, van Weerden WM, Jonkers J, Dekker R, Taneja N, Kanaar R, van Gent DC
Cancer research 2022 Feb 1;82(3):510-520

The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population.

Alenezi WM, Milano L, Fierheller CT, Serruya C, Revil T, Oros KK, Behl S, Arcand SL, Nayar P, Spiegelman D, Gravel S, Mes-Masson AM, Provencher D, Foulkes WD, El Haffaf Z, Rouleau G, Bouchard L, Greenwood CMT, Masson JY, Ragoussis J, Tonin PN
Cancers 2022 Apr 30;14(9)

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.

Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernández A, Viaplana C, Villacampa G, Guzmán M, Rodríguez O, Grueso J, Jiménez J, Arenas EJ, Degasperi A, Dias JML, Forment JV, O'Connor MJ, Déas O, Cairo S, Zhou Y, Musolino A, Caldas C, Nik-Zainal S, Clarke RB, Nuciforo P, Díez O, Serres-Créixams X, Peg V, Espinosa-Bravo M, Macarulla T, Oaknin A, Mateo J, Arribas J, Dienstmann R, Bellet M, Oliveira M, Saura C, Gutiérrez-Enríquez S, Balmaña J, Serra V
Cancer research 2022 Apr 15;82(8):1646-1657

Lysophosphatidic Acid-Induced EGFR Transactivation Promotes Gastric Cancer Cell DNA Replication by Stabilizing Geminin in the S Phase.

Zhao H, Gezi G, Tian X, Jia P, Morigen M, Fan L
Frontiers in pharmacology 2021;12:706240

Dual Inhibition of PARP and the Intra-S/G2 Cell Cycle Checkpoints Results in Highly Effective Radiosensitization of HPV-Positive HNSCC Cells.

Hintelmann K, Berenz T, Kriegs M, Christiansen S, Gatzemeier F, Struve N, Petersen C, Betz C, Rothkamm K, Oetting A, Rieckmann T
Frontiers in oncology 2021;11:683688

Clinical consequences of BRCA2 hypomorphism.

Castells-Roca L, Gutiérrez-Enríquez S, Bonache S, Bogliolo M, Carrasco E, Aza-Carmona M, Montalban G, Muñoz-Subirana N, Pujol R, Cruz C, Llop-Guevara A, Ramírez MJ, Saura C, Lasa A, Serra V, Diez O, Balmaña J, Surrallés J
NPJ breast cancer 2021 Sep 9;7(1):117

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.

Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS
Cancer discovery 2021 Nov;11(11):2812-2827

Rapid initiation of cell cycle reentry processes protects neurons from amyloid-β toxicity.

Ippati S, Deng Y, van der Hoven J, Heu C, van Hummel A, Chua SW, Paric E, Chan G, Feiten A, Fath T, Ke YD, Haass NK, Ittner LM
Proceedings of the National Academy of Sciences of the United States of America 2021 Mar 23;118(12)

The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks.

van Wijk LM, Kramer CJH, Vermeulen S, Ter Haar NT, de Jonge MM, Kroep JR, de Kroon CD, Gaarenstroom KN, Vrieling H, Bosse T, Vreeswijk MPG
Cancers 2021 Jun 15;13(12)

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.

Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V
Annals of oncology : official journal of the European Society for Medical Oncology 2021 Dec;32(12):1590-1596

Loss of polycystins suppresses deciliation via the activation of the centrosomal integrity pathway.

Gerakopoulos V, Ngo P, Tsiokas L
Life science alliance 2020 Sep;3(9)

The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas.

van Wijk LM, Vermeulen S, Meijers M, van Diest MF, Ter Haar NT, de Jonge MM, Solleveld-Westerink N, van Wezel T, van Gent DC, Kroep JR, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG
Cancers 2020 Sep 29;12(10)

CHD7 and 53BP1 regulate distinct pathways for the re-ligation of DNA double-strand breaks.

Rother MB, Pellegrino S, Smith R, Gatti M, Meisenberg C, Wiegant WW, Luijsterburg MS, Imhof R, Downs JA, Vertegaal ACO, Huet S, Altmeyer M, van Attikum H
Nature communications 2020 Nov 13;11(1):5775

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.

Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC
Nature communications 2020 May 29;11(1):2662

RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of BRCA1-Null Cancers.

Krais JJ, Wang Y, Bernhardy AJ, Clausen E, Miller JA, Cai KQ, Scott CL, Johnson N
Cancer research 2020 Jul 1;80(13):2848-2860

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.

Coussy F, El-Botty R, Château-Joubert S, Dahmani A, Montaudon E, Leboucher S, Morisset L, Painsec P, Sourd L, Huguet L, Nemati F, Servely JL, Larcher T, Vacher S, Briaux A, Reyes C, La Rosa P, Lucotte G, Popova T, Foidart P, Sounni NE, Noel A, Decaudin D, Fuhrmann L, Salomon A, Reyal F, Mueller C, Ter Brugge P, Jonkers J, Poupon MF, Stern MH, Bièche I, Pommier Y, Marangoni E
Science translational medicine 2020 Feb 19;12(531)

Cell Cycle Analysis and Relevance for Single-Cell Gating in Mass Cytometry.

Rein ID, Notø HØ, Bostad M, Huse K, Stokke T
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2020 Aug;97(8):832-844

Immunohistochemical assessment of chromatin licensing and DNA replication factor 1, geminin, and γ-H2A.X in oral epithelial precursor lesions and squamous cell carcinoma.

Siril YJ, Kouketsu A, Oikawa M, Takahashi T, Kumamoto H
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2019 Nov;48(10):888-896

An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.

Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, van Wijk LM, Revilla SA, Theeuwsen R, van de Ven M, van Roosmalen MJ, Ponsioen B, Ho VWH, Neel BG, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG, van Diest PJ, Witteveen PO, Jonges T, Bos JL, van Oudenaarden A, Zweemer RP, Snippert HJG, Kloosterman WP, Clevers H
Nature medicine 2019 May;25(5):838-849

HSF2BP Interacts with a Conserved Domain of BRCA2 and Is Required for Mouse Spermatogenesis.

Brandsma I, Sato K, van Rossum-Fikkert SE, van Vliet N, Sleddens E, Reuter M, Odijk H, van den Tempel N, Dekkers DHW, Bezstarosti K, Demmers JAA, Maas A, Lebbink J, Wyman C, Essers J, van Gent DC, Baarends WM, Knipscheer P, Kanaar R, Zelensky AN
Cell reports 2019 Jun 25;27(13):3790-3798.e7

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.

de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, Smit VTHBM, Nout RA, Glaire MA, Church DN, Vrieling H, Job B, Boursin Y, de Kroon CD, Rouleau E, Leary A, Vreeswijk MPG, Bosse T
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Feb 1;25(3):1087-1097

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.

Venneker S, Kruisselbrink AB, Briaire-de Bruijn IH, de Jong Y, van Wijnen AJ, Danen EHJ, Bovée JVMG
Cancers 2019 Dec 2;11(12)

Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder.

van den Tempel N, Naipal KAT, Raams A, van Gent DC, Franckena M, Boormans JL, Kanaar R
PloS one 2018;13(12):e0209101

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.

Nacson J, Krais JJ, Bernhardy AJ, Clausen E, Feng W, Wang Y, Nicolas E, Cai KQ, Tricarico R, Hua X, DiMarcantonio D, Martinez E, Zong D, Handorf EA, Bellacosa A, Testa JR, Nussenzweig A, Gupta GP, Sykes SM, Johnson N
Cell reports 2018 Sep 25;24(13):3513-3527.e7

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V
EMBO molecular medicine 2018 Dec;10(12)

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.

Fleury H, Carmona E, Morin VG, Meunier L, Masson JY, Tonin PN, Provencher D, Mes-Masson AM
Oncotarget 2017 Jun 20;8(25):40152-40168

In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.

Chatalic KL, Konijnenberg M, Nonnekens J, de Blois E, Hoeben S, de Ridder C, Brunel L, Fehrentz JA, Martinez J, van Gent DC, Nock BA, Maina T, van Weerden WM, de Jong M
Theranostics 2016;6(1):104-17

Combined B, T and NK Cell Deficiency Accelerates Atherosclerosis in BALB/c Mice.

Cheng F, Twardowski L, Reifenberg K, Winter K, Canisius A, Pross E, Fan J, Schmitt E, Shultz LD, Lackner KJ, Torzewski M
PloS one 2016;11(8):e0157311

Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma.

Bhide SA, Thway K, Lee J, Wong K, Clarke P, Newbold KL, Nutting CM, Harrington KJ
British journal of cancer 2016 Sep 27;115(7):825-30

Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest.

Schaaf L, Schwab M, Ulmer C, Heine S, Mürdter TE, Schmid JO, Sauer G, Aulitzky WE, van der Kuip H
Cancer research 2016 May 15;76(10):2868-75

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.

Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK, kConFab Investigators, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N
Cancer research 2016 May 1;76(9):2778-90

APC/C(CDC20) and APC/C play pivotal roles in the process of embryonic development in Artemia sinica.

Zhang M, Yao F, Luan H, Zhao W, Jing T, Zhang S, Hou L, Zou X
Scientific reports 2016 Dec 19;6:39047

Cell cycle kinetic analysis of colorectal neoplasms using a new automated immunohistochemistry-based cell cycle detection method.

Tomono A, Itoh T, Yanagita E, Imagawa N, Kakeji Y
Medicine 2015 Jan;94(4):e501

Whole genomes redefine the mutational landscape of pancreatic cancer.

Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA, Australian Pancreatic Cancer Genome Initiative, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM
Nature 2015 Feb 26;518(7540):495-501

Cell cycle and apoptosis regulatory proteins, proliferative markers, cell signaling molecules, CD209, and decorin immunoreactivity in low-grade myxofibrosarcoma and myxoma.

Cates JM, Memoli VA, Gonzalez RS
Virchows Archiv : an international journal of pathology 2015 Aug;467(2):211-6

Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.

Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens JW, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter JP, Vreeswijk MP, Jager A, van Gent DC
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Sep 15;20(18):4816-26

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.

Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A, Turner NC
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Dec 15;16(24):6159-68

No comments: Submit comment

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: human testis tissue were subjected to SDS PAGE followed by western blot with 10802-1-AP(GMNN antibody) at dilution of 1:300
Sample type: tissue

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: IP Result of anti-GMNN (IP:10802-1-AP, 4ug; Detection:10802-1-AP 1:1000) with HEK-293 cells lysate 4500ug.
Sample type: cell line

Supportive validation

Submitted by: Proteintech Group (provider)
Main image
Experimental details: The Geminin antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human Geminin. This antibody recognizes human,mouse,rat antigen. The Geminin antibody has been validated for the following applications: ELISA, WB, IP, IHC analysis.
Appendix: 10802-1-AP.pdf

: Show more